MDGL Madrigal Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MDGL

Price (delayed)

$284.49

Market cap

$6.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$23.13

Enterprise value

$5.56B

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum ...

Highlights
The company's quick ratio has surged by 176% YoY and by 73% QoQ
The equity has soared by 110% since the previous quarter
The company's net income fell by 41% YoY and by 19% QoQ
The debt has grown by 39% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.madrigalpharma.com
Peers: NWBO

Key stats

What are the main financial stats of MDGL
Market
Shares outstanding
21.31M
Market cap
$6.06B
Enterprise value
$5.56B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.65
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$430.06M
EBITDA
-$429.49M
Free cash flow
-$391.12M
Per share
EPS
-$23.13
Free cash flow per share
-$19.55
Book value per share
$42.76
Revenue per share
$0
TBVPS
$53.86
Balance sheet
Total assets
$1.08B
Total liabilities
$231.52M
Debt
$117.72M
Equity
$850.76M
Working capital
$959.61M
Liquidity
Debt to equity
0.14
Current ratio
9.39
Quick ratio
9.26
Net debt/EBITDA
1.18
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-78.5%
Return on equity
-128.6%
Return on invested capital
-121.5%
Return on capital employed
-44.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MDGL stock price

How has the Madrigal Pharmaceuticals stock price performed over time
Intraday
0.36%
1 week
-0.96%
1 month
3.32%
1 year
41.3%
YTD
22.95%
QTD
1.55%

Financial performance

How have Madrigal Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$454.2M
Net income
-$444.28M
Gross margin
N/A
Net margin
N/A
MDGL's operating income is down by 45% YoY and by 19% QoQ
The company's net income fell by 41% YoY and by 19% QoQ

Growth

What is Madrigal Pharmaceuticals's growth rate over time

Valuation

What is Madrigal Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 28% YoY and by 16% from the previous quarter
The equity has soared by 110% since the previous quarter
The stock's price to book (P/B) is 85% less than its last 4 quarters average of 44.9 and 70% less than its 5-year quarterly average of 22.0

Efficiency

How efficient is Madrigal Pharmaceuticals business performance
Madrigal Pharmaceuticals's ROIC has soared by 66% YoY and by 2.2% from the previous quarter
The ROE has soared by 55% YoY and by 41% from the previous quarter
MDGL's return on assets is up by 33% year-on-year and by 21% since the previous quarter

Dividends

What is MDGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MDGL.

Financial health

How did Madrigal Pharmaceuticals financials performed over time
The current ratio has surged by 179% year-on-year and by 75% since the previous quarter
The company's quick ratio has surged by 176% YoY and by 73% QoQ
The debt is 86% smaller than the equity
The equity has soared by 110% since the previous quarter
Madrigal Pharmaceuticals's debt to equity has shrunk by 75% YoY and by 52% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.